帕唑帕尼

Description

Pazopanib · CAS 444731-52-6 · C21H23N7O2S. UNII 7RN5DR86CK. LogP: 3.3.

Identification

CAS Registry Number	444731-52-6
PubChem CID	10113978
Molecular formula	C21H23N7O2S
IUPAC name	5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide
UNII (FDA)	7RN5DR86CK

Computed Descriptors

Molecular Weight	437.5
XLogP3	3.1
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	5
Exact Mass	437.16339418
Monoisotopic Mass	437.16339418
Topological Polar Surface Area	127
Heavy Atom Count	31
Formal Charge	0

Physical & Chemical Properties

LogP	3.3

Physical description & handling notes

• Based on the stability data a shelf-life of 24 months will be applied to the product, with no special storage conditions requirements.
• Stable if stored as directed; avoid strong oxidizing agents. /Pazopanib hydrochloride/
• Thermal decomposition may produce toxic gases such as carbon monoxide, carbon dioxide, and nitrogen oxides. /Pazopanib hydrochloride/
• White to slightly yellow solid. Practically insoluble above pH 4 in aqueous media/Pazopanib hydrochloride/
• Oral: Tablets, film-coated: 200 mg (of pazopanib), Votrient (GlaxoSmithKline). /Pazopanib hydrochloride/

GHS Hazard Classification

Reported hazard statements	H302 (50%), H315 (50%), H319 (50%), H335 (50%), H361 (25%), H373 (25%), H411 (25%)

Documented Uses

• THERAPEUTIC CATEGORY: Antineoplastic
• Preparation: A. Boloor et al., World Intellectual Property Organization patent 02059110 (2002 to Glaxo); eidem, United States of America patent 7105530 (2006 to SKB).
• The manufacturing process is a standard wet granulation process and consists of the following steps: granulation; milling; drying; blending and compression. The tablets are then film-coated.
• Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
• Pazopanib is a multi-kinase inhibitor active against vascular endothelial growth factor receptors-1, -2 and -3 that is used in the therapy of advanced renal cell carcinoma and soft tissue sarcomas. Pazopanib therapy is commonly associated with transient elevations in serum aminotransferase during therapy and has been linked to rare, but occasionally severe and even fatal cases of clinically apparent acute liver injury.
• Breast Feeding; Lactation; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors; Tyrosine Kinase Inhibitors;

Synonyms

Pazopanib; 444731-52-6; GW786034; 5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide; pazopanibum; DTXSID8048733; 7RN5DR86CK; NSC-752782; GW780604; GW-780604; 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide; DTXCID1028659; CHEBI:71219; Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-; 5-({4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide; Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-

Frequently Asked Questions

What are the CAS number and molecular formula of Pazopanib?

CAS 444731-52-6; molecular formula C21H23N7O2S; molecular weight — g/mol.

What other names is Pazopanib known by?

Pazopanib, 444731-52-6, GW786034, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide, pazopanibum, DTXSID8048733.

Is Pazopanib classified as hazardous?

Hazard statements reported: H302, H315, H319, H335, H361.

What are the key physical properties of Pazopanib?

LogP: 3.3.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.